Results 21 to 30 of about 1,095,480 (156)

Nephrogenic Systemic Fibrosis Associated with Gadolinium Use [PDF]

open access: yesJournal of the Formosan Medical Association, 2008
Nephrogenic systemic fibrosis (NSF) is an idiopathic, progressive, systemic fibrosis that occurs in patients with renal diseases. Recently, gadolinium-containing contrast (Gd-contrast) has become a suspected causal factor for NFS.
Chi-Chao Chao   +5 more
doaj   +3 more sources

A moderate response to plasmapheresis in nephrogenic systemic fibrosis

open access: yesClinics and Practice, 2011
Nephrogenic systemic fibrosis (NSF) is a recently identified idiopathic cutaneous fibrosing disorder that occurs in the setting of renal failure. The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium ...
Pelin Ustuner   +3 more
doaj   +2 more sources

[Nephrogenic systemic fibrosis]. [PDF]

open access: yesGiornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2008
Nephrogenic systemic fibrosis (NSF) is a new, rare, and severe disease occurring in patients with renal failure who have been exposed to gadolinium. The pathogenesis of NSF is not completely known. In fact, the first warning about a significant relationship between NSF and gadolinium (a contrast medium used in magnetic resonance imaging) was only ...
Cavallini L.   +5 more
  +16 more sources

Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance [PDF]

open access: yesJournal of Cardiovascular Magnetic Resonance, 2012
Nephrogenic Systemic Fibrosis is a rare condition appearing only in patients with severe renal impairment or failure and presents with dermal lesions and involvement of internal organs.
Reiter Theresa   +6 more
doaj   +5 more sources

Alone on a collagen island: Unique findings of osseous sclerotic bodies in nephrogenic systemic fibrosis [PDF]

open access: yesJAAD Case Reports, 2023
Emily R. Gordon, BA   +8 more
doaj   +2 more sources

Development and Validation of Algorithms for Systemic Sclerosis Identification in Electronic Health Record Data. [PDF]

open access: yesACR Open Rheumatol
Objective The aim of this study was to develop and validate International Classification of Diseases (ICD) code–based algorithms for identifying systemic sclerosis (SSc) cases within electronic health record (EHR) data and to evaluate algorithm performance. Methods We identified patients with at least one ICD, Ninth Revision (ICD‐9)/ICD‐10 code for SSc
Ozen G, O'Rorke M, Romitti P, Domsic R.
europepmc   +2 more sources

Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review [PDF]

open access: yesInternational Journal of Environmental Research and Public Health, 2021
Wioletta Mędrzycka-Dąbrowska   +2 more
exaly   +2 more sources

An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. [PDF]

open access: yesPLoS ONE, 2015
Nephrogenic systemic fibrosis (NSF) is a rare but serious disorder disease affecting patients with advanced renal disease. Although multiple studies have indicated an association between gadolinium-based contrast agents (GBCAs) and NSF, some studies ...
Bin Zhang   +4 more
doaj   +2 more sources

Gadolinio y fibrosis sistémica nefrogénica Gadolinium and nephrogenic systemic fibrosis

open access: yesRevista Argentina de Radiología, 2012
Inicialmente llamada dermopatía fibrosante nefrogénica, la fibrosis sistémica nefrogénica (FSN) está fuertemente ligada a la inyección endovenosa de medios de contraste -basados en gadolinio- en pacientes con insuficiencia renal.
Claudia Cejas, Cecilia Acuña
doaj   +1 more source

Nephrogenic systemic fibrosis. [PDF]

open access: yesF1000 Med Rep, 2010
Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency. This review discusses recent advances in our understanding of the pathophysiology and clinical approach to patients with ...
Braverman IM, Cowper S.
europepmc   +9 more sources

Home - About - Disclaimer - Privacy